Format

Send to

Choose Destination
Dermatol Surg. 2016 Feb;42(2):157-66. doi: 10.1097/DSS.0000000000000602.

Melanoma Outcomes in Transplant Recipients With Pretransplant Melanoma.

Author information

1
*Department of Dermatology University of California, San Francisco, San Francisco, California; †Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland; ‡Information Management Services, Rockville, Maryland; §Department of Epidemiology & Biostatistics, University of California, San Francisco, San Francisco, California; ‖Cancer Prevention Institute of California, Fremont, California; ¶Rutgers School of Public Health, Piscataway, New Jersey; #Cancer Epidemiology Services, New Jersey Department of Health, Trenton, New Jersey.

Abstract

BACKGROUND:

There are limited data on outcomes in transplant recipients with a history of pretransplant melanoma.

OBJECTIVE:

To determine whether pretransplant melanoma is associated with differences in survival or posttransplant melanoma risk.

MATERIALS AND METHODS:

We evaluated the outcomes of 185,039 US transplant recipients from the Transplant Cancer Match Study. We also evaluated the impact of transplantation on 141,441 patients with melanoma identified in cancer registries.

RESULTS:

There were 336 transplant recipients (0.18%) with pretransplant melanoma; they had increased risk of melanoma-specific mortality (hazard ratio [HR], 27; 95% confidence interval [CI], 11-64, p < .0001), overall mortality (HR, 1.3; 95% CI, 1.0-1.5, p = .02), and incident melanoma (HR, 5.4; 95% CI, 2.9-9.8, p < .0001) after transplant, compared with recipients without pretransplant melanoma. The 10-year absolute risk difference was 2.97% for melanoma-specific mortality, 3.68% for incident melanoma, and 14.32% for overall mortality. Among the 141,441 patients with melanoma in the general population, 68 (0.05%) subsequently received a transplant. Transplantation increased melanoma-specific mortality, but not significantly (HR, 1.7; 95% CI, 0.61-4.5, p = .32).

CONCLUSION:

Pretransplant melanoma is associated with increased melanoma-specific mortality, overall mortality, and incident melanoma after transplant. Nonetheless, the rarity of melanoma-related events supports the current practice for listing transplant candidates with a history of melanoma.

PMID:
26818209
PMCID:
PMC6263147
DOI:
10.1097/DSS.0000000000000602
[Indexed for MEDLINE]
Free PMC Article

Publication types, MeSH terms, Grant support

Publication types

MeSH terms

Grant support

Supplemental Content

Full text links

Icon for Wolters Kluwer Icon for PubMed Central
Loading ...
Support Center